Biocept traded at $0.94 this Friday July 1st, decreasing $0.0001 or 0.01 percent since the previous trading session. Looking back, over the last four weeks, Biocept lost 31.89 percent. Over the last 12 months, its price fell by 77.67 percent. Looking ahead, we forecast Biocept to be priced at 0.88 by the end of this quarter and at 0.81 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
Daily Change

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Peers Price Day Year
Abbott 110.22 1.57 1.45% -6.62%
Becton, Dickinson and Co. 251.80 5.27 2.14% 1.35%
Biocept 0.94 -0.0001 -0.01% -77.67%
Celldex Therapeutics 22.70 -4.26 -15.80% -32.94%
Plus Therapeutics, Inc. 0.54 0 0% -77.59%
Quest Diagnostics 136.68 3.70 2.78% 2.52%
General Electric 63.54 -0.13 -0.20% -40.55%
Illumina 191.04 6.68 3.62% -59.76%
Roche Holding 320.40 1.85 0.58% -8.34%
Thermo Fisher Scientific 548.27 4.99 0.92% 6.81%

Indexes Price Day Year
USND 11128 99.11 0.90% -23.99%

Biocept, Inc. is an early stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor nucleic acid, including circulating tumor deoxyribonucleic acid (ctDNA) and circulating tumor ribonucleic acid (ctRNA), assays using a standard blood sample or liquid biopsy. Its blood and cerebrospinal fluid (CSF) assays are intended to provide information to aid healthcare providers by identifying tumor cells associated with progression or metastasis and identifying specific oncogenic alterations that may qualify a subset of cancer patients for targeted therapy. The Company's Target-Selector CTC and molecular platforms provide both biomarker detection as well as monitoring capabilities and require only a patient blood sample or CSF sample to inform treatment decisions. It also offers sensitive polymerase chain reaction (PCR) based assay through Aegea Biotechnologies, Inc. (Aegea) for detecting the COVID-19 virus.